Effect of Supplemental Vitamin D on Skeletal Muscle Function in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT ID: NCT00914810
Last Updated: 2013-06-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
39 participants
INTERVENTIONAL
2009-06-30
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D and Chronic Obstructive Lung Disease
NCT01416701
Vitamin D Supplementation in Patients With COPD
NCT02122627
Trial of Vitamin D Supplementation in Chronic Obstructive Pulmonary Disease
NCT00977873
Vitamin D as Treatment for Chronic Obstructive Pulmonary Disease (COPD)
NCT00666367
Examining the Role of Vitamin D in Asthma and Chronic Obstructive Pulmonary Disease (COPD)
NCT00851695
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitamin D
Cholecalciferol (2000 I.U. daily)
Vitamin D (cholecalciferol)
2000 I.U. daily for 6 weeks
Placebo
Placebo capsule (sugar pill daily)
Placebo
Placebo (sugar pill) daily for 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D (cholecalciferol)
2000 I.U. daily for 6 weeks
Placebo
Placebo (sugar pill) daily for 6 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Forced expiratory volume in one second (FEV1) \< or = 50% of predicted
* Smoking history of at least 10 pack-years
* Able to ambulate independently or with the use of an ambulatory assist device (such as a cane or walker)
Exclusion Criteria
* Primary diagnosis of asthma
* Uncompensated heart failure
* Heart attack in the previous 6 months
* Kidney disease (glomerular filtration rate \< 45 mL/min/1.73m2)
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Minneapolis Veterans Affairs Medical Center
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ken M. Kunisaki
Assistant Professor of Medicine and Staff Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ken M. Kunisaki, M.D.
Role: PRINCIPAL_INVESTIGATOR
Minneapolis Veterans Affairs Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Minneapolis VA Medical Center
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4129-A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.